TABLE 3

NCI SBIR–Funded TRT Grants from 2009 to 2010

Year	Company	Award type	Disease	Isotope	Target or targeted agent	Aims
2009	Immunomedics, Inc.	Phases I and II	Non-Hodgkin lymphoma	⁹⁰Y	Epratuzumab	Reevaluate maximum tolerated dose for fractionated weekly injection of ⁹⁰Y-epratuzumab (previously found to be 2 × 0.74 GBq/m²) in standard phase I setting; proceed into phase II trial to evaluate response and safety
2009	Acaduceus Pharmaceutics, Inc.	Phase I	Prostate cancer	⁹⁰Y	BBN-RGD	Synthesize ⁹⁰Y-BBN-RGD peptide radiotracers and characterize their hydrophilicity, receptor binding affinity, and cytotoxicity in vitro; determine pharmacokinetics/pharmacodynamics, radiation dosimetry, and maximum tolerable dose of ⁹⁰Y-BBN-RGD in mice
2009	SibTech, Inc.	Phases I and II	Breast cancer	¹⁷⁷Lu	VEGF	Phase II: Establish dose and time dependence for scVEGF/Lu-induced destruction of tumor vasculature and potential roles of overexpressed endogenous VEGF; establish optimal sequence for scVEGF/Lu-doxorubicin combination as adjuvant therapy for recurrent breast cancer
2009	Molecular Insight Pharmaceuticals, Inc.	Phases I and II	Metastatic melanoma	¹³¹I	Ioflubenzamide	Phase II: Complete clinical imaging study on 12 subjects with confirmed metastatic malignant melanoma to determine safety and organ dosimetry; select therapeutic starting dose for therapy escalation study
2009	Molecular Insight Pharmaceuticals, Inc.	Phases I and II	Metastatic melanoma	¹³¹I	MIP-1145	Phase II: Develop continuous flow production process and good-manufacturing-practice production; perform animal safety and toxicity testing
2010	Molecular Insight Pharmaceuticals, Inc.	Phase I	Prostate cancer	¹³¹I	PSMA	Obtain preclinical data on ¹³¹I-labeled MIP-1072 and establish its potential to target PSMA-expressing tumors; determine in vitro prostate cancer cells binding characteristics; preform organ distribution and treatment efficacy studies in rodent tumor models
2010	IsoTherapeutics Group, LLC	Phases I and II	Bone metastases	¹⁵³Sm	DOTMP	Phase II: Manufacture clinical-grade CycloSam; verify that clinical-grade CycloSam has same biodistribution as obtained in phase I, using rats and dogs; perform dose escalation studies treating canine bone tumors to determine maximum dose that can be given without clinically significant suppression of bone marrow
2010	Solixia, Inc.	Phase I	Ovarian cancer	¹⁸⁸Re	Folate receptor	Prepare ¹⁸⁸Re-labeled hot-dot conjugates with folic acid and test performance of these conjugates in cell-binding assays to determine optimal formulations; assess radiation dosimetry of most promising conjugate in relevant animal model

BBN = bobesin; RGD = cyclic arginine-glycine-aspartic acid; VEGF = vascular endothelial growth factor; PSMA = prostate-specific membrane antigen; GC = glucosamine conjugate.
All information in this table is publicly accessible at http://projectreporter.nih.gov/reporter.cfm.